Mathangi Gopalakrishnan

Dr. Mathangi Gopalakrishnan


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ABAlison L. Blackman
Alison L. Blackman
PJPraneeth Jarugula
Praneeth Jarugula
DNDavid Nicolau
David Nicolau
SCSai Ho Chui
Sai Ho Chui
MJManjari Joshi
Manjari Joshi
MGMathangi Gopalakrishnan
Mathangi Gopalakrishnan
Background: Linezolid standard dosing is fixed at 600 mg q12h for adults. Literature suggests critically-ill, obese patients require higher doses. The study aim is two-fold: (i) to describe linezolid PK and (ii) to evaluate if PK/PD target attainment is achieved with standard dosing in critically-ill, obese patients with severe SSTIs. Methods: Adult patients with a body mass index (BMI) ≥ 30 kg/m2 and receiving IV linezolid from August 2018 to April 2019 were eligible for consent in this prospective study. Severe SSTIs were defined as necrotizing fasciitis, myonecrosis, or SSTI with sepsis syndrome. Four blood samples were collected at steady state at 1, 3, 5 hours post-infusion and as a trough. Target attainment was defined as achieving AUC0-24h/MIC ≥ 100 hr*mg/L. Monte Carlo simulations were used to determine probability of target attainment (PTA). Results: Eleven patients were included in the study. The median BMI was 45.7 kg/m2 and median total body weight (TBW) was 136.0 kg. Seven patients received standard linezolid doses and four received 600 mg q8h. A one-compartment model described linezolid PK. Based on AUC0-24h/MIC targets, for non-cirrhotic patients at 140 kg, PTA with standard linezolid doses was 100%, 98.8%, 34.1%, and 0% for MICs 0.5, 1, 2, and 4 mg/L, respectively. Conclusion: Target attainment ≥ 90% is not achieved with standard linezolid doses for non-cirrhotic patients ≥ 140 kg with MICs ≥ 2 mg/L. This study adds to accumulating evidence that standard linezolid doses may not be adequate for all patients.

3 March 2020 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
MGMathangi Gopalakrishnan
Mathangi Gopalakrishnan
HZHao Zhu
Hao Zhu
TFTiffany R. Farchione
Tiffany R. Farchione
MMMitchell Mathis
Mitchell Mathis
MMMehul Mehta
Mehul Mehta
IYIslam Younis
Islam Younis
Concerns of increasing placebo response and declining treatment effect in acute schizophrenia trials have been reported for new drug applications (NDAs) submitted to the US Food and Drug Administration (FDA) during an 18-year period from 1991 through January 2009 (ie, the pre-2009 period). Current exploratory analyses provide an update in the trends observed in placebo response, treatment effect, and dropout rates for NDAs submitted from February 2009 to 2015 (ie, the post-2009 period). Clinical trial data from all acute schizophrenia trials that were submitted as part of NDAs to the US FDA during a 24-year period from 1991 to 2015. Aggregate trial-level efficacy data from multicenter, multiregional, randomized, placebo-controlled, 4- to 8-week, fixed- and flexible-dose trials in adult schizophrenia patients were compiled. There were 12 NDAs pre-2009 (32 trials, N = 11,567) and 3 NDAs post-2009 (14 trials, N = 6,434). Baseline demographic and disease variables and scores on the Positive and Negative Syndrome Scale (PANSS) were summarized and compared for the two time periods (pre-2009 and post-2009). The primary efficacy measure was mean change from baseline to endpoint in total PANSS score obtained by last-observation-carried-forward analysis. Regional differences in placebo response and treatment effect were explored for the two time periods based on baseline patient characteristics, sample size, and dropout rates. Trials were predominantly multiregional (10/14; 71%) during the post-2009 period compared to the pre-2009 period (11/32; 34%). The overall trial success rates were 57% (8/14) and 78% (25/32) during the post-2009 and pre-2009 periods, respectively. Comparing the pre-2009 and post-2009 periods, the mean placebo response (change from baseline in PANSS score) increased from -6.4 to -10.5 and the mean treatment effect (drug response - placebo response) declined from -8.6 to -5.8 , with substantial differences observed especially in North American trials. In North American trials, placebo response increased from -4.3 (pre-2009) to -8.5 (post-2009), and treatment effect decreased from -9.0 (pre-2009) to -3.4 (post-2009). The difference in placebo response (pre- and post-2009: -10.0 and -11.3 ) and treatment effect (pre and post-2009: -8.1 and -6.4 ) in multiregional trials for the two time periods remained minimal. Baseline disease severity remained similar in the pre- and post-2009 time periods, with PANSS scores ranging between 85 and 100. Trials with higher mean baseline PANSS scores tended to show higher treatment effect irrespective of the time period and region. Post-2009, dropout rates were higher (55%) in North American trials compared with 33% in multiregional trials, similar to the pre-2009 trend. The continuing trend of increasing placebo responses and decreasing treatment effects in schizophrenia trials over the 24-year period does remain of great concern, especially with respect to North American trials. However, given the current global nature of drug development, close attention to trial conduct and reexamination of design elements for future trials may be warranted.

26 July 2017 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
APArindam Pal
Arindam Pal
SSSrinivas Shenoy
Srinivas Shenoy
AGAnirudh Gautam
Anirudh Gautam
SMSagar Munjal
Sagar Munjal
JNJing Niu
Jing Niu
JGJoga Gobburru
Joga Gobburru
COX-2 inhibitors can be effective for acute migraine, but none is supplied in a rapidly absorbed, ready-to-use oral liquid formulation. DFN-15, a novel oral liquid formulation of celecoxib, is being developed for the acute treatment of migraine with or without aura. Clinical studies with this formulation are ongoing.

16 February 2018 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
ABAshima Bhatia
Ashima Bhatia
STShraddha Tawade
Shraddha Tawade
MMMushtaque Mastim
Mushtaque Mastim
EKEliford Ngaimisi Kitabi
Eliford Ngaimisi Kitabi
MGMathangi Gopalakrishnan
Mathangi Gopalakrishnan
KKK. M. Prasanna Kumar
K. M. Prasanna Kumar

7 April 2017 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JNJing Niu
Jing Niu
CSChristie Scheuerell
Christie Scheuerell
SMShailly Mehrotra
Shailly Mehrotra
SKSharon Karan
Sharon Karan
SPShannon Puhalla
Shannon Puhalla
JBJan H. Beumer
Jan H. Beumer

14 October 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BSBabajide Shenkoya
Babajide Shenkoya
VYVenkata Kashyap Yellepeddi
Venkata Kashyap Yellepeddi
KMKatrina Mark
Katrina Mark
MGMathangi Gopalakrishnan
Mathangi Gopalakrishnan
A knowledge gap exists in infant tetrahydrocannabinol (THC) data to guide breastfeeding recommendations for mothers who use cannabis. In the present study, a paired lactation and infant physiologically based pharmacokinetic (PBPK) model was developed and verified. The verified model was used to simulate one hundred virtual lactating mothers (mean age: 28 years, body weight: 78 kg) who smoked 0.32 g of cannabis containing 14.14% THC, either once or multiple times. The simulated breastfeeding conditions included one-hour post smoking and subsequently every three hours. The mean peak concentration (Cmax) and area under the concentration–time curve (AUC(0–24 h)) for breastmilk were higher than in plasma (Cmax: 155 vs. 69.9 ng/mL; AUC(0–24 h): 924.9 vs. 273.4 ng·hr/mL) with a milk-to-plasma AUC ratio of 3.3. The predicted relative infant dose ranged from 0.34% to 0.88% for infants consuming THC-containing breastmilk between birth and 12 months. However, the mother-to-infant plasma AUC(0–24 h) ratio increased up to three-fold (3.4–3.6) with increased maternal cannabis smoking up to six times. Our study demonstrated the successful development and application of a lactation and infant PBPK model for exploring THC exposure in infants, and the results can potentially inform breastfeeding recommendations.